Aura Biosciences Inc
Research Aura Biosciences Inc (AURA) on Bullrun: market cap USD 676.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAURA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 676.76M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 45.64M
- Free cash flow-USD 32.52M
Valuation Snapshot
latest market cap is USD 676.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 106.19M | -USD 85.19M | n/a | -1.76 | USD 59.52M | USD 17.38M | USD 136.91M |
| FY2024 | USD 0 | -USD 86.92M | -USD 81.06M | n/a | -1.75 | USD 31.69M | USD 18.77M | USD 151.97M |
| FY2023 | USD 0 | -USD 76.41M | -USD 64.56M | n/a | -1.93 | USD 41.06M | USD 19.56M | USD 225.85M |
| FY2022 | USD 0 | -USD 58.76M | -USD 55.70M | n/a | -1.96 | USD 121.58M | USD 20.86M | USD 195.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 676.76M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 346.55M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 410.99M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 436.44M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 388.92M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 496.01M | n/a | n/a | n/a |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aura Biosciences Inc's market cap?
Aura Biosciences Inc's market capitalization is USD 676.76M.
What does Aura Biosciences Inc do?
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.